Can Novo’s Oral Semaglutide Shake Up Indian Diabetes Segment?

 
• By Anju Ghangurde

Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?

diabetes
Can oral semaglutide disrupt the Indian market? • Source: Alamy

More from India

More from Focus On Asia